Unique Therapy for Multiple Inflammatory Diseases with Dr. Jean-Marc Steens Abivax

Published: June 4, 2019, 5:46 p.m.

Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.\xa0

Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.\xa0

#ulcerativecolitis

Abivax

\xa0

\xa0